Pages that link to "Q37811594"

The following pages link to Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile (Q37811594):

Displaying 21 items.

• In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class (Q24530841) (← links)
• Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions (Q28329970) (← links)
• An overview of GnRH antagonists in infertility treatments. Introduction (Q35165328) (← links)
• Clinical pharmacokinetics of endocrine agents used in advanced breast cancer (Q35722575) (← links)
• Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions (Q36650783) (← links)
• Drug Treatment in Precocious Puberty (Q36663803) (← links)
• Current Concepts in the Treatment of Genitourinary Tract Disorders in the Older Individual (Q36715789) (← links)
• Acute Transverse Myelitis Associated with Buserelin Use during IVF. (Q36763418) (← links)
• Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer (Q36972786) (← links)
• Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders (Q36972988) (← links)
• The Treatment of Precocious Puberty (Q37085207) (← links)
• Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders (Q40398462) (← links)
• Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty (Q40487158) (← links)
• A stability indicating capillary electrophoresis method for analysis of buserelin (Q42919027) (← links)
• Effects of gonadotrophin-releasing hormone agonists on human ovarian steroid secretion in vivo and in vitro-results of a prospective, randomized in-vitro fertilization study (Q48890058) (← links)
• The effect of Buserelin versus conventional antiandrogenic treatment in patients with T2-4NXM1 prostatic cancer. A prospective, randomized multicentre phase III trial. The "Danish Buserelin Study Group". (Q50559898) (← links)
• Long-Acting Gonadotropin-Releasing Hormone Agonists in the Differential Diagnosis of Male Precocious Puberty (Q52191827) (← links)
• Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist. (Q55015269) (← links)
• The Role of Tocotrienol in Preventing Male Osteoporosis-A Review of Current Evidence (Q64080243) (← links)
• Disposition of 3H-labelled buserelin continuously infused into rats (Q73165278) (← links)
• Protection afforded by maltosyl-beta-cyclodextrin against alpha-chymotrypsin-catalyzed hydrolysis of a luteinizing hormone-releasing hormone agonist, buserelin acetate (Q73849591) (← links)